Polar Capital LLP Acquires Shares of 904,416 Immunomedics, Inc. (IMMU)

Share on StockTwits

Polar Capital LLP acquired a new stake in Immunomedics, Inc. (NASDAQ:IMMU) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 904,416 shares of the biopharmaceutical company’s stock, valued at approximately $12,906,000. Polar Capital LLP owned about 0.47% of Immunomedics as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Exane Derivatives acquired a new stake in shares of Immunomedics in the fourth quarter valued at approximately $32,000. Karp Capital Management Corp bought a new position in shares of Immunomedics in the fourth quarter valued at $33,000. North Star Investment Management Corp. bought a new position in shares of Immunomedics in the fourth quarter valued at $50,000. Pearl River Capital LLC bought a new position in shares of Immunomedics in the fourth quarter valued at $66,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Immunomedics by 16.3% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,151 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 1,140 shares in the last quarter. Institutional investors own 84.64% of the company’s stock.

IMMU stock opened at $17.94 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 13.45 and a quick ratio of 13.45. Immunomedics, Inc. has a one year low of $11.55 and a one year high of $27.33. The firm has a market cap of $3.42 billion, a price-to-earnings ratio of -17.42 and a beta of 2.08.

Several equities analysts recently weighed in on the stock. ValuEngine raised shares of Immunomedics from a “buy” rating to a “strong-buy” rating in a research note on Thursday. BidaskClub raised shares of Immunomedics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, March 6th. HC Wainwright assumed coverage on shares of Immunomedics in a research note on Monday, March 4th. They issued a “buy” rating and a $28.00 target price for the company. Zacks Investment Research cut shares of Immunomedics from a “hold” rating to a “sell” rating in a research note on Thursday, January 24th. Finally, B. Riley set a $28.00 target price on shares of Immunomedics and gave the company a “buy” rating in a research note on Wednesday, January 23rd. One analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $28.00.

WARNING: “Polar Capital LLP Acquires Shares of 904,416 Immunomedics, Inc. (IMMU)” was published by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.tickerreport.com/banking-finance/4222926/polar-capital-llp-acquires-shares-of-904416-immunomedics-inc-immu.html.

About Immunomedics

Immunomedics, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively.

See Also: Does the Step Transaction Doctrine Affect a Backdoor Roth IRA?

Institutional Ownership by Quarter for Immunomedics (NASDAQ:IMMU)

Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Mitie Group PLC  Receives Consensus Recommendation of “Buy” from Brokerages
Mitie Group PLC Receives Consensus Recommendation of “Buy” from Brokerages
Critical Comparison: Weatherford International  versus Its Peers
Critical Comparison: Weatherford International versus Its Peers
Sanford C. Bernstein Analysts Give Beiersdorf  a €91.00 Price Target
Sanford C. Bernstein Analysts Give Beiersdorf a €91.00 Price Target
Wolverine World Wide  Downgraded by ValuEngine
Wolverine World Wide Downgraded by ValuEngine
Dycom Industries  Stock Rating Lowered by ValuEngine
Dycom Industries Stock Rating Lowered by ValuEngine
FY2020 EPS Estimates for Innergex Renewable Energy Inc  Lowered by Raymond James
FY2020 EPS Estimates for Innergex Renewable Energy Inc Lowered by Raymond James


© 2006-2019 Ticker Report